acute on chronic liver failure aclf market insight

DelveInsight’s ‘Acute-On-Chronic Liver Failure (ACLF)–Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Acute-On-Chronic Liver Failure (ACLF), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acute-On-Chronic Liver Failure (ACLF) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted ACLF symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Acute-On-Chronic Liver Failure (ACLF) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030

Acute-On-Chronic Liver Failure (ACLF) Disease Understanding and Treatment Algorithm

Acute-on-Chronic Liver Failure (ACLF)Overview

Acute-on -chronic liver failure (ACLF) is a syndrome in patients with chronic liver disease with or without previously diagnosed cirrhosis characterized by acute hepatic decompensation resulting in liver failure (jaundice and prolongation of the international normalized ratio), and one or more extrahepatic organ failures, that is associated with increased risk for mortality within a period of 28 days and up to 3 months from onset.

The natural history of chronic liver disease in a subset of patients is progression to cirrhosis. Cirrhosis has two broad stages. The onset of jaundice, ascites, variceal bleeding, or hepatic encephalopathy heralds the onset of decompensated cirrhosis, whereas the stage where there is an absence of any of these complications is compensated cirrhosis. When viral, drug, alcohol, or ischemic hepatitis, surgery, or sepsis are superimposed upon chronic liver disease with or without either stage of cirrhosis, there is worsening of liver disease that may result in hepatic and extrahepatic organ failure. Furthermore, ACLF is classified into three groups, according to the underlying liver disease ACLF: type A ACLF (patients with underlying non-cirrhotic chronic liver disease), type B ACLF (patients with previously compensated cirrhosis), and C ACLF (patients with previous decompensated cirrhosis). Thus, ACLF is a late stage in the natural history of chronic liver disease with hepatic and extrahepatic organ failure.

Currently, treatment strategies are limited to symptomatic relief and organ support, indicating the necessity for novel biomarkers, drugs, and devices for the management of ACLF. A multidisciplinary management strategy is required to ensure the early detection of organ dysfunction. At the same time, engagement with the liver transplant community is needed to define a new allocation policy for this subset of patients. Methods to further define and characterize ACLF involve additional investigation of the metabolomics profile of patients with ACLF, while G-CSF administration and cell transplantation seem to be novel and promising therapeutic interventions to improve patient outcomes. Furthermore, prospective clinical studies are required to fully elucidate the modifiable factors that predispose patients to ACLF and improve the understanding of this devastating syndrome, while developing a personalized management plan for individual patients based on their clinical and genetic characteristics.

Acute-on-Chronic Liver Failure (ACLF) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Acute-on -chronic liver failure (ACLF) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Acute-on -chronic liver failure (ACLF) market report gives a thorough understanding of ACLF symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides ACLF symptoms of treatment algorithms and treatment guidelines for ACLF symptoms in the US, Europe, and Japan.

Acute-on-Chronic Liver Failure (ACLF) Epidemiology

The epidemiology division’s Acute-on -chronic liver failure (ACLF) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acute-on -chronic liver failure (ACLF) epidemiology segmented as the Total Cases of Acute-On-Chronic Liver Failure (ACLF), Cases of Acute-On-Chronic Liver Failure (ACLF) by Grades, Organ Failure Associated with Acute-On-Chronic Liver Failure, Potential participating events of Acute-On-Chronic Liver Failure. The report includes the Cases of ACLF in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Acute-on-Chronic Liver Failure (ACLF) Epidemiology

The epidemiology segment also provides the Acute-on -chronic liver failure (ACLF) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total 7MM cases of Acute-on-Chronic Liver Failure (ACLF) were 61,026 in 2020.

Acute-on-Chronic Liver Failure (ACLF) Drug Chapters

The drug chapter segment of the Acute-on -chronic liver failure (ACLF) report encloses the detailed analysis of ACLF marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Acute-on -chronic liver failure (ACLF) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Currently, there is no specific effective treatment available for patients with ACLF, and therefore treatment is based on organ support and treatment of associated complications. When ACLF is associated with a precipitating factor (i.e., bacterial infections, GI bleeding, alcoholism, and drug toxicity), early identification and treatment of the precipitating factor are essential. However, this may not prevent the development or the worsening of the syndrome. In addition, in up to 40% of patients, a precipitating factor may not be identified. Moreover, available data suggest that although the precipitating factor may be the trigger of ACLF, it may not be an essential predictor of prognosis.

Products detail in the report…

Acute-On-Chronic Liver Failure (ACLF) Emerging Drugs

Grifols Therapeutics evaluates the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects. The primary physiological function of albumin results from its contribution to plasma colloid oncotic pressure and transport function. Albumin stabilizes circulating blood volume and is a carrier of hormones, enzymes, medicinal products, and toxins. Other physiological functions include antioxidant properties, free radical scavenging, and capillary membrane integrity.

Products detail in the report…

Acute-On-Chronic Liver Failure (ACLF) Market Outlook

The Acute-On-Chronic Liver Failure (ACLF) market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Acute-On-Chronic Liver Failure (ACLF) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Acute-On-Chronic Liver Failure (ACLF) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Acute-On-Chronic Liver Failure (ACLF) market in 7MM is expected to change in the study period 2018–2030.

Key Findings

This section includes a glimpse of the Acute-On-Chronic Liver Failure (ACLF) market in 7MM. The market size of ACLF in the seven major markets was found to be USD 71.25 million in 2020, and the market is estimated to increase at a CAGR of 26.77% for the study period (2018–2030).

The United States Market Outlook

This section provides a total of Acute-On-Chronic Liver Failure (ACLF) market size and market size by therapies in the United States.

The United States accounts for the highest ACLF market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Acute-On-Chronic Liver Failure (ACLF) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Acute-On-Chronic Liver Failure (ACLF) market size and market size by therapies in Japan are also mentioned.

Acute-On-Chronic Liver Failure (ACLF) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis Acute-On-Chronic Liver Failure (ACLF) market uptake by drugs, patient uptake by therapies, and drug sales.

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Acute-On-Chronic Liver Failure (ACLF) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Acute-On-Chronic Liver Failure (ACLF) key players involved in developing targeted therapeutics.

Major players include PE-A 5% (Grifols Therapeutics) and Hepastem (Promethera Biosciences) being assessed as potential therapies to be available in the market in the coming future.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Acute-On-Chronic Liver Failure (ACLF) emerging therapies.

Reimbursement Scenario in Acute-On-Chronic Liver Failure (ACLF)

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working Acute-On-Chronic Liver Failure (ACLF) domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Acute-On-Chronic Liver Failure (ACLF) market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Acute-On-Chronic Liver Failure (ACLF) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Acute-On-Chronic Liver Failure (ACLF) explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
• Comprehensive insight has been provided into the Acute-On-Chronic Liver Failure (ACLF) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Acute-On-Chronic Liver Failure (ACLF) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Acute-On-Chronic Liver Failure (ACLF) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Acute-On-Chronic Liver Failure (ACLF) market

Report Highlights

• In the coming years, Acute-On-Chronic Liver Failure (ACLF) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Acute-On-Chronic Liver Failure (ACLF) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for ACLF. The launch of emerging therapies will significantly impact the Acute-On-Chronic Liver Failure (ACLF) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for ACLF.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Acute-On-Chronic Liver Failure (ACLF) Report Insights

• Patient Population
• Therapeutic Approaches
• Acute-On-Chronic Liver Failure (ACLF) Pipeline Analysis
• Acute-On-Chronic Liver Failure (ACLF) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Acute-On-Chronic Liver Failure (ACLF) Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Acute-On-Chronic Liver Failure (ACLF) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Acute-On-Chronic Liver Failure (ACLF) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Acute-On-Chronic Liver Failure (ACLF) Market share (%) distribution in 2020, and how would it look in 2030?
• What would be the Acute-On-Chronic Liver Failure (ACLF) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2030)?
• What are the market’s key findings across 7MM, and which country will have the largest Acute-On-Chronic Liver Failure (ACLF) market Size during the forecast period (2021–2030)?
• At what CAGR, the Acute-On-Chronic Liver Failure (ACLF) market is expected to grow by 7MM during the forecast period (2021–2030)?
• What would be the Acute-On-Chronic Liver Failure (ACLF) market outlook across the 7MM during the forecast period (2021–2030)?
• What would be the Acute-On-Chronic Liver Failure (ACLF) market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of Acute-On-Chronic Liver Failure (ACLF)?
• What is the historical Acute-On-Chronic Liver Failure (ACLF) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Acute-On-Chronic Liver Failure (ACLF) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population about Acute-On-Chronic Liver Failure (ACLF)?
• Out of all 7MM countries, which country would have the highest Cases of Acute-On-Chronic Liver Failure (ACLF) population during the forecast period (2021–2030)?
• At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Acute-On-Chronic Liver Failure (ACLF)?
• What are the current treatment guidelines for treating Acute-On-Chronic Liver Failure (ACLF) in the USA, Europe, and Japan?
• What are the Acute-On-Chronic Liver Failure (ACLF) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Acute-On-Chronic Liver Failure (ACLF)?
• How many therapies are developed by each company for the treatment of Acute-On-Chronic Liver Failure (ACLF)?
• How many emerging therapies are in the mid-stage and late development stages to treat Acute-On-Chronic Liver Failure (ACLF)?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute-On-Chronic Liver Failure (ACLF) therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute-On-Chronic Liver Failure (ACLF) and their status?
• What are the key designations that have been granted for the emerging therapies for Acute-On-Chronic Liver Failure (ACLF)?
• What are the global historical and forecasted markets of Acute-On-Chronic Liver Failure (ACLF)?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Acute-On-Chronic Liver Failure (ACLF) market
• To understand the future market competition in the Acute-On-Chronic Liver Failure (ACLF) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Acute-On-Chronic Liver Failure (ACLF) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Acute-On-Chronic Liver Failure (ACLF) market
• To understand the future market competition in the Acute-On-Chronic Liver Failure (ACLF) market